newsfilter
← Latest News
GlobeNewswire·

Trevena Reports Second Quarter 2024 Results and Provides Business Update

TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term analgesic effect and differentiated mechanism of action in